Guided Therapeutics, Inc.

Guided Therapeutics LightTouch Cervical Scan FDA Clinical Trial Indicates Adolescent's Risk for Cervical Disease on Par with Adult Women

Published in Food and Drug Law Weekly, April 9th, 2010

Women 16 to 20 years of age are just as likely to have significant cervical disease as women 21 and older, according to results of a U.S. Food and Drug Administration (FDA) pivotal clinical trial of the Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) LightTouch™ Cervical Scanner, being presented at the American Society for Colposcopy and Cervical Pathology biennial meeting.

The study, which is the basis for seeking FDA approval, indicated that 18 percent of the 290 adolescent subjects in the trial presented with significant disease, the same as the group of 1,317 women aged 21 and older. Five of the adolescent subjects that were missed by the current standard...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly

Source: Food and Drug Law Weekly (2010-04-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry